Literature DB >> 15210735

Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap?

Janet E Dancey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15210735     DOI： 10.1200/JCO.2004.04.934

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer.

Authors:  Aleksandra Franovic; Lakshman Gunaratnam; Karlene Smith; Isabelle Robert; David Patten; Stephen Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

2.  Epidermal growth factor receptor expression in renal cell carcinoma: rationale for therapy with sidling blockade.

Authors:  Ronald M Bukowski
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

3.  EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.

Authors:  Toshiyuki Sakaeda; Noboru Okamura; Akinobu Gotoh; Toshiro Shirakawa; Shuji Terao; Masahi Morioka; Kenji Tokui; Hisato Tanaka; Tsutomu Nakamura; Mariko Yagi; Yoshihiro Nishimura; Mitsuhiro Yokoyama; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

Review 4.  [Application of tissue microarrays for the diagnosis, prognosis and therapeutic decision making in renal cell carcinoma].

Authors:  A S Merseburger; J Hennenlotter; D Schilling; K D Sievert; R Küfer; M A Kuczyk
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

Review 5.  Genomics of renal cell cancer-- does it provide breakthrough?

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2006-03-23       Impact factor: 3.201

6.  EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma.

Authors:  Gordana Dorđević; Koviljka Matušan Ilijaš; Ita Hadžisejdić; Anton Maričić; Blaženka Grahovac; Nives Jonjić
Journal:  J Biomed Sci       Date:  2012-04-05       Impact factor: 8.410

7.  Is membranous location of EGFR or EGFRvIII immunostaining associated with good prognosis in renal cell carcinoma?

Authors:  H Modjtahedi; M P Cunningham
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

8.  Integrative omics analyses broaden treatment targets in human cancer.

Authors:  Sohini Sengupta; Sam Q Sun; Kuan-Lin Huang; Clara Oh; Matthew H Bailey; Rajees Varghese; Matthew A Wyczalkowski; Jie Ning; Piyush Tripathi; Joshua F McMichael; Kimberly J Johnson; Cyriac Kandoth; John Welch; Cynthia Ma; Michael C Wendl; Samuel H Payne; David Fenyö; Reid R Townsend; John F Dipersio; Feng Chen; Li Ding
Journal:  Genome Med       Date:  2018-07-27       Impact factor: 11.117

9.  A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.

Authors:  Molly F Kulesz-Martin; James Lagowski; Susan Olson; Aaron Wortham; Toni West; George Thomas; Christopher Ryan; Jeffrey W Tyner
Journal:  Cancer Biol Ther       Date:  2012-11-28       Impact factor: 4.742
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.